Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Pharmaceuticals Could Become The Next Vertex
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC
32,662 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Ally Bridge Group NY LLC
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC
Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
2 Under-the-Radar Stocks to Buy and Hold
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Corcept Therapeutics (NASDAQ:CORT) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) Head to Head Contrast
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Head-To-Head Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Praxsyn (OTCMKTS:PXYN)
John Paulson's Strategic Moves: Madrigal Pharmaceuticals Inc. Sees a -3.09% Impact
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday